RxDoctor Payments Data

Anthony Lombardo, MD

Cardiovascular Disease · Newport News, VANPI 1801008420

Payments from drug & device makers

$972in general payments, 2019–2025

Across 46 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$183
  • Astellas Pharma US Inc$157
  • Abiomed$87
  • Boston Scientific$80
  • E.r. Squibb & Sons, L.L.C.$73
  • Inari Medical, Inc.$50
  • plus $342 from 13 others

What the payments were for

  • Food & beverage$972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$972 in reported general payments places this provider in the 40th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$190,968
Medicare patients
2,849
Services billed
5,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban272$314,419
XareltoRivaroxaban139$173,382
EntrestoSacubitril/Valsartan62$70,636
MultaqDronedarone Hcl33$51,968
Repatha SureclickEvolocumab28$40,267
FarxigaDapagliflozin Propanediol15$13,498
BrilintaTicagrelor19$10,730
Metoprolol Succinate624$8,502
Rosuvastatin Calcium275$3,102
Ranolazine ErRanolazine15$3,094
Atorvastatin Calcium311$2,451
Diltiazem 24hr Er (Cd)Diltiazem Hcl116$2,443
ClopidogrelClopidogrel Bisulfate258$2,244
Isosorbide Mononitrate ErIsosorbide Mononitrate212$2,146
Valsartan84$1,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$314,419272 claims
Johnson & JohnsonXarelto$183$173,382139 claims
NovartisEntresto$24$70,63662 claims
AstraZenecaFarxiga, Brilinta$31$24,22834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →